Combination of several direct-acting antiviral agents will be necessary to overcome viral resistance in interferon-free treatment regimens for chronic HCV infection. HCV p7 inhibitors may be part of such combination regimens. Understanding why amantadine, despite showing inhibition of HCV p7 in vitro, appears ineffective in clinical trials, may help in the design of novel HCV p7 inhibitors. So far it is unknown whether viral escape mutations within HCV p7 explain the ineffectiveness of amantadine in vivo.
Methods
Pretreatment HCV p7 was directly sequenced in 157 consecutive patients with chronic HCV genotype 1b infection who had been treated with amantadine/placebo plus pegylated interferon (PEG-IFN)-α2a/ribavirin within a multicentre clinical trial. Triple therapy was preceded by 2 weeks of amantadine/placebo monotherapy. In nine patients, clonal sequencing was performed at baseline and after 2 weeks of amantadine/placebo monotherapy.
Results
Changes of the relative frequency of amino acid substitutions by ≥20% between pretreatment and week 2 of monotherapy were considered potential resistance mutations if they were only found in patients receiving amantadine but not in patients receiving placebo. Seven substitutions fulfilling these criteria were identified in the subset of patients with clonal sequencing. However, none of these substitutions were associated with treatment outcome in the complete cohort of patients receiving triple therapy with amantadine.
Conclusions
Potential viral escape mutations within HCV p7 do not seem to play a major role for treatment response to antiviral therapy with amantadine and PEG-IFN-α2a/ribavirin in patients with chronic HCV genotype 1b infection.
References
1.
El-SeragH.B.Hepatocellular carcinoma and hepatitis C in the United States. Hepatology2002; 36Suppl 1: S74–S83.
2.
HoofnagleJ.H.Course and outcome of hepatitis C. Hepatology2002; 36Suppl 1: S21–S29.
3.
SeeffL.B.Natural history of chronic hepatitis C. Hepatology2002; 36Suppl 1: S35–S46.
ForestierN., SusserS., WelkerM.Telaprevir resistance mutations in patients with hepatitis C who relapsed after sequential therapy with telaprevir, peg-interferon alfa 2a and ribavirin. Hepatology2007; 46Suppl 1: 255A–256A.
6.
ForestierN., ReesinkH., WeeginkC.Antiviral activity of telaprevir (VX-950) and peginterferon alfa-2a in patients with hepatitis C. Hepatology2007; 46: 640–648.
7.
HézodeC., ForestierN., DusheikoG.Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med2009; 360: 1839–1850.
8.
KiefferT.L., SarrazinC., MillerJ.S.Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients. Hepatology2007; 46: 631–639.
9.
ReesinkH.W., ZeuzemS., WeeginkC.Rapid decline of viral RNA in hepatitis C patients treated with VX-950: a Phase Ib, placebo-controlled, randomized study. Gastroenterology2006; 131: 997–1002.
10.
Rodriguez-TorresM., LawitzE.J., McHutchisonJ.Final results of patients treated with peg-interferon-alfa-2A (PEG-IFN) and ribavirin (RBV) follow-on therapy after 28-day treatment with the hepatitis C protease inhibitor telaprevir (VX-950), PEG-IFN and RBV. Hepatology2007; 46Suppl 1: 314A–315A.
11.
SarrazinC., KiefferT.L., BartelsD.Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. Gastroenterology2007; 132: 1767–1777.
12.
SarrazinC., RouzierR., WagnerF.SCH 503034, a novel hepatitis C virus protease inhibitor, plus pegylated interferon alpha-2b for genotype 1 nonresponders. Gastroenterology2007; 132: 1270–1278.
13.
GriffinS., StgelaisC., OwsiankaA.M., PatelA.H., RowlandsD., HarrisM.Genotype-dependent sensitivity of hepatitis C virus to inhibitors of the p7 ion channel. Hepatology2008; 48: 1779–1790.
14.
LuscombeC.A., HuangZ., MurrayM.G., MillerM., WilkinsonJ., EwartG.D.A novel hepatitis C virus p7 ion channel inhibitor, BIT225, inhibits bovine viral diarrhea virus in vitro and shows synergism with recombinant interferon-alpha-2b and nucleoside analogues. Antiviral Res2010; 86: 144–153.
15.
WozniakA.L., GriffinS., RowlandsD.Intracellular proton conductance of the hepatitis C virus p7 protein and its contribution to infectious virus production. PLoS Pathog2010; 6: e1001087.
16.
JonesC.T., MurrayC.L., EastmanD.K., TasselloJ., RiceC.M.Hepatitis C virus p7 and NS2 proteins are essential for production of infectious virus. J Virol2007; 81: 8374–8383.
17.
LinC., LindenbachB.D., PragaiB.M., McCourtD.W., RiceC.M.Processing in the hepatitis C virus E2-NS2 region: identification of p7 and two distinct E2-specific products with different C termini. J Virol1994; 68: 5063–5073.
18.
BrohmC., SteinmannE., FrieslandM.Characterization of determinants important for hepatitis C virus p7 function in morphogenesis by using trans-complementation. J Virol2009; 83: 11682–11693.
19.
SakaiA., ClaireM.S., FaulkK.The p7 polypeptide of hepatitis C virus is critical for infectivity and contains functionally important genotype-specific sequences. Proc Natl Acad Sci U S A2003; 100: 11646–11651.
20.
SteinmannE., PeninF., KallisS., PatelA.H., BartenschlagerR., PietschmannT.Hepatitis C virus p7 protein is crucial for assembly and release of infectious virions. PLoS Pathog2007; 3: e103.
21.
VieyresG., BrohmC., FrieslandM.Subcellular localization and function of an epitope-tagged p7 viroporin in hepatitis C virus-producing cells. J Virol2013; 87: 1664–1678.
22.
GriffinS.D., BealesL.P., ClarkeD.S.The p7 protein of hepatitis C virus forms an ion channel that is blocked by the antiviral drug, Amantadine. FEBS Lett2003; 535: 34–38.
23.
ClarkeD., GriffinS., BealesL.Evidence for the formation of a heptameric ion channel complex by the hepatitis C virus p7 protein in vitro. J Biol Chem2006; 281: 37057–37068.
24.
PremkumarA., WilsonL., EwartG.D., GageP.W.Cation-selective ion channels formed by p7 of hepatitis C virus are blocked by hexamethylene amiloride. FEBS Lett2004; 557: 99–103.
25.
GriffinS.D., HarveyR., ClarkeD.S., BarclayW.S., HarrisM., RowlandsD.J.A conserved basic loop in hepatitis C virus p7 protein is required for amantadine-sensitive ion channel activity in mammalian cells but is dispensable for localization to mitochondria. J Gen Virol2004; 85: 451–461.
26.
PavlovićD., NevilleD.C., ArgaudO.The hepatitis C virus p7 protein forms an ion channel that is inhibited by long-alkyl-chain iminosugar derivatives. Proc Natl Acad Sci U S A2003; 100: 6104–6108.
27.
StGelaisC., TuthillT.J., ClarkeD.S., RowlandsD.J., HarrisM., GriffinS.Inhibition of hepatitis C virus p7 membrane channels in a liposome-based assay system. Antiviral Res2007; 76: 48–58.
28.
DeltenreP., HenrionJ., CanvaV.Evaluation of amantadine in chronic hepatitis C: a meta-analysis. J Hepatol2004; 41: 462–473.
29.
ChenJ., ShiJ., XieW.F., ZengX., LinY.Meta-analysis: amantadine may lower the efficacy of pegylated interferon plus ribavirin in treatment-naive hepatitis C genotype 1 patients. Int J Infect Dis2012; 16: e748–e752.
30.
MangiaA., LeandroG., HelblingB.Combination therapy with amantadine and interferon in naive patients with chronic hepatitis C: meta-analysis of individual patient data from six clinical trials. J Hepatol2004; 40: 478–483.
31.
ChanJ., O'RiordanK., WileyT.E.Amantadine's viral kinetics in chronic hepatitis C infection. Dig Dis Sci2002; 47: 438–442.
32.
MaynardM., PradatP., BaillyF.Amantadine triple therapy for non-responder hepatitis C patients. Clues for controversies (ANRS HC 03 BITRI). J Hepatol2006; 44: 484–490.
33.
HayA.J., WolstenholmeA.J., SkehelJ.J., SmithM.H.The molecular basis of the specific anti-influenza action of amantadine. EMBO J1985; 4: 3021–3024.
34.
SuzukiH., SaitoR., MasudaH., OshitaniH., SatoM., SatoI.Emergence of amantadine-resistant influenza A viruses: epidemiological study. J Infect Chemother2003; 9: 195–200.
35.
FosterT.L., VerowM., WozniakA.L.Resistance mutations define specific antiviral effects for inhibitors of the hepatitis C virus p7 ion channel. Hepatology2011; 54: 79–90.
36.
StGelaisC., FosterT.L., VerowM.Determinants of hepatitis C virus p7 ion channel function and drug sensitivity identified in vitro. J Virol2009; 83: 7970–7981.
37.
MihmU., GrigorianN., WelschC.Amino acid variations in hepatitis C virus p7 and sensitivity to antiviral combination therapy with amantadine in chronic hepatitis C. Antivir Ther2006; 11: 507–519.
38.
von WagnerM., HofmannW.P., TeuberG.Placebo-controlled trial of 400 mg amantadine combined with peginterferon alfa-2a and ribavirin for 48 weeks in chronic hepatitis C virus-1 infection. Hepatology2008; 48: 1404–1411.
39.
KatoN., HijikataM., OotsumaY.Molecular cloning of the human hepatitis C virus genome from Japanese patients with non-A, non-B hepatitis 82. Proc Natl Acad Sci U S A1990; 87: 9524–9528.
40.
Van de PeerY., De WachterR.TREECON for Windows: a software package for the construction and drawing of evolutionary trees for the Microsoft Windows environment. Comput Appl Biosci1994; 10: 569–570.
41.
SarrazinC., BergT., LeeJ.H.Mutations in the protein kinase-binding domain of the NS5A protein in patients infected with hepatitis C virus type 1a are associated with treatment response. J Infect Dis2000; 181: 432–441.
42.
SarrazinC., BrucknerM., HerrmannE.Quasispecies heterogeneity of the carboxy-terminal part of the E2 gene including the PePHD and sensitivity of hepatitis C virus 1b isolates to antiviral therapy. Virology2001; 289: 150–163.
43.
MontserretR., SaintN., VanbelleC.NMR structure and ion channel activity of the p7 protein from hepatitis C virus. J Biol Chem2010; 285: 31446–31461.
44.
CastelainS., BonteD., PeninF.Hepatitis C Virus p7 membrane protein quasispecies variability in chronically infected patients treated with interferon and ribavirin, with or without amantadine. J Med Virol2007; 79: 144–154.
45.
KwongA.D., NajeraI., BechtelJ.Sequence and phenotypic analysis for resistance monitoring in hepatitis C virus drug development: recommendations from the HCV DRAG. Gastroenterology2011; 140: 755–760.
46.
SteinmannE., WhitfieldT., KallisS.Antiviral effects of amantadine and iminosugar derivatives against hepatitis C virus. Hepatology2007; 46: 330–338.
47.
SteinmannE., PietschmannT.Hepatitis C virus p7-a viroporin crucial for virus assembly and an emerging target for antiviral therapy. Viruses2010; 2: 2078–2095.
48.
BermanH.M., WestbrookJ., FengZ.The Protein Data Bank. Nucleic Acids Res2000; 28: 235–242.
